New drug cocktail tested for Tough-to-Treat blood cancer
NCT ID NCT04302324
Summary
This study is testing a combination of four existing drugs (daratumumab, clarithromycin, pomalidomide, and dexamethasone) for people with multiple myeloma whose cancer has returned or stopped responding to prior treatment. The goal is to see if this specific mix can better control the cancer compared to older standard treatments. Participants will receive the drugs until their cancer worsens or they experience unacceptable side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Weill Cornell Medicine - Multiple Myeloma Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.